Pay in 4 interest-free payments of $7.01 Learn more
Ships within 48 hours · Estimated delivery Oct 10 - Oct 15
BILLY BELIEVER Disappeared
Lay out all supplies
Retatrutide, on the other hand, is a specific, man-made molecule
Even with powerful injectable therapies, there remains a group of patients for whom bariatric surgery is still the stronger long-term answer
What the FDA Requires in the BLA Efficacy Data: TRIUMPH-4: 28.7% weight loss Complete TRIUMPH-1: 28.3% weight loss Complete TRIUMPH-2: 20.8% weight loss (obesity + diabetes) Complete TRIUMPH-3: 22.6% weight loss (obesity + cardiovascular disease) Complete, MACE data not statistically significant Safety Data: Side effect profile across all four populations Short-term and medium-term adverse events, including the dysesthesia signal (up to 20.9% at 12mg) Drug interactions, especially with diabetes medications Manufacturing Data: Scale-up capability for millions of doses per month Quality control and stability data Cold chain distribution logistics Realistic Approval Scenarios With the BLA filing point now expected (Q1 2027), the remaining uncertainty is largely in the FDA review itself not in whether or when Lilly files
